Autologous hemotopoietic stem cell transplantation for treatment of patients with lymphoma

Objective: To investigate the efficacy and safety of hig h dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation (APBSCT) in curing lymphoma. Methods: 5 malignant lymphoma patients were treated with high dose chemoradiotherapy with APBSCT, there were 4 non-hodgkin's lymphoma and one Hodgkin's lymphoma. The mobilization plan of autologous peripheral blood stem cell:one was Ara-c 10 g/m\+2+G-CSF. 4 non-hodgkin's lymphoma were VP-16 1 500 mg/m\+2+G-CSF. After mobilization, collected MNC≥3.85×10\+8/kg, CD 34\++ cells≥6.96×10\+5/kg, and CFU-GM≥4.41×10\+5/kg. Primary treatment: 1 NHL was CTX 4 g/m\+2+VP-16 800 mg/m\+2+total body irradiation 780 cGy. Others were CTX 4 g/m\+2, VP-16 800 mg/m\+2, BCNU 450 mg/m\+2, and complementary irradiation in the primary sites after transplant, Follow 9-43 months,median follow-up of 18 months. Results: All patients obtained sustained hemolopoietic reconstitution. The disease received CR after transplantation. Up to 10 th May 2004, All cases were event-free survival. Conclusions: High dose chemoradiotherapy supported by APBSCT in the treatment of lymphoma is a safe and effective modality, however further clinic investigation is warranted.